In a world where a single mutation in DNA can doom a child to a lifelong struggle with infections and inflammations, a new project promises an advanced solution: not symptom relief, but complete correction of the defect at the root of the immune system.
The AEGIS project (Affordable Gene Editing Therapies for Immune System Diseases of Children) has received powerful reinforcement: the Advanced Research Projects Agency for Health (ARPA-H) has allocated up to 27,7 million dollars for the development of affordable gene editing methods for children with congenital immune disorders. The consortium, led by the Innovative Genomics Institute at the University of California, Berkeley — an institution founded by Nobel laureate and co-creator of CRISPR Jennifer Doudna — brings together academic, clinical, and industrial partners to turn complex genetic technology into accessible treatment. Over five years, the consortium intends to develop and test affordable CRISPR-based approaches for more than 500 rare genetic conditions causing immunodeficiency in children.
Mayo Clinic will serve as one of the three main clinical centers of the project — alongside UCLA and the University of Utah. Mayo experts, with deep experience in pediatric transplantation and cell therapies, will select patients, conduct clinical trials, and ensure long-term follow-up of treatment. This role underscores the clinic's growing authority in genomic medicine: Mayo is a member of the Primary Immunodeficiency Treatment Consortium and an accredited transplant center. Together with UCLA scientist Donald Kohn (principal investigator of the clinical trial with 35 years of experience in developing gene therapies for pediatric immunodeficiencies) and colleagues from other centers, Mayo specialists will evaluate the safety and efficacy of editing hematopoietic stem cells — the cells that give rise to the entire immune system.
The scale of the project's ambition deserves attention: the team intends to treat 10 children over five years and simultaneously build a universal platform that will radically reduce costs and development time. If traditional gene therapy development takes years and costs millions, AEGIS plans to develop a personalized therapy in less than three months at a cost below 200 thousand dollars per patient. This is achieved by combining base and prime editing technologies with innovative delivery via lipid nanoparticles — a method already tested in animal models.
Unlike traditional approaches requiring lifelong immunosuppressive therapy or risky bone marrow transplantation, AEGIS aims to create a one-time intervention: edit the patient's stem cells outside the body, then return them to restore normal immune function permanently. This is especially critical for ultra-rare diseases where traditional treatment options do not exist at all or are available to only two or three patients worldwide.
Avni Joshi, Mayo Clinic's leading specialist in pediatric allergy and immunology, emphasized the project's key idea: "the combination of advanced editing technologies with innovative delivery methods will allow not just alleviating symptoms but eliminating the root of the problem and relieving families of the burden of constant treatment." This vision is shared by all project participants, including leaders from UCLA, Stanford, the University of Utah, as well as specialists from Princeton, UC San Diego, Emory, and the Danaher Corporation — a company that has already demonstrated success in scaling CRISPR therapies.
The AEGIS project is part of ARPA-H's THRIVE program (Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines), which funds seven different research groups working on rare genetic diseases. The platform being created under AEGIS, according to its authors, will become a template for accelerating the development of therapies for hundreds of other rare genetic diseases — not only immunodeficiencies but also disorders affecting other organ systems. This will transform precision genomic medicine from a bespoke "artisanal" production into a scalable and accessible system where every child can receive personalized therapy.
Thus, AEGIS demonstrates how the combination of academic, clinical, and industrial resources can turn revolutionary genetic tools into real life-saving help for children whose lives depend on the precise correction of a single error in the DNA code.
